Drug profile

The FDA adverse-event record for Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid

17 FDA reports name Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#1951 of 2,679
by report volume (all drugs)
17
adverse-event reports
88.2%
death-coded share
Cattle
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid ranks #1937 of 2679 by total reports (17). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1937
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid has 17 reports now versus 17 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid changes

Signature read: Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid's 88.2% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
15
Deaths Reported
88.2%
Death-coded share of reports

Active Ingredients

Clostridium ChauvoeiClostridium NovyiClostridium Perfringens Type C Bacterin ToxoidClostridium Perfringens Type D Bacterin ToxoidClostridium SepticumClostridium SordelliiHaemophilus Somnus Bacterin Toxoid

Administration Routes

SubcutaneousUnknown

Species Affected

Cattle 17

Most Affected Breeds

Cattle (other) 10
Aberdeen Angus 5
Crossbred Bovine/Cattle 1
Cattle (unknown) 1

Most Reported Reactions

Death 14
Lack of efficacy - NOS 8
Lack of efficacy (bacteria) - NOS 4
Necropsy performed 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Open mouth breathing 1
Depression 1
Panting 1
Recumbency 1
Foam in the nose 1
NT - Abnormal necropsy finding NOS 1
Lack of efficacy (bacteria NOS) 1

Outcome Breakdown

Died
15 (44.1%)
Recovered/Normal
11 (32.4%)
Outcome Unknown
5 (14.7%)
Ongoing
2 (5.9%)
Recovered with Sequela
1 (2.9%)

Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid (#1951 of 2,679 by report volume); death-coded 88.2%. PlainBreed drug row · death-coded share stamp 88.2% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →